EUVIMEDEUVIMED entdecken
Klinische Studie

Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases

Karol Majewski, Paulina Żelechowska, Ewa Brzezińska-Błaszczyk

Clinical and Investigative Medicine · 19.02.2017 · 40 (1) · E34-E39

DOI: 10.25011/cim.v40i1.28052 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical and Investigative Medicine, erschienen am 19.02.2017. Verfasst von Karol Majewski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Immunology, Medical University of Lodz; Pulmonary Disease Hospital, Lodz . email@email.com. Die Arbeit wurde bisher 10-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The antimicrobial peptide cathelicidin LL-37 plays a role in the immune response in the course of lung infections; however, the exact role of LL-37 in defense mechanisms against bacteria within the respiratory tract is has not been precisely described. The aim of our study was to evaluate LL-37 concentrations in the serum of pulmonary tuberculosis (TB) patients, patients with pneumonia caused by Gram-positive and Gram-negative bacteria and to compare them with those of healthy subjects.

Methods

Thirty TB patients, 30 patients with pneumonia caused by Gram-positive bacteria, 30 patients with pneumonia caused by Gram-negative bacteria, and 30 healthy control subjects were enrolled in the study. Serum LL-37 concentration was measured using an enzyme-linked immunosorbent assay (ELISA).

Results

The mean (± SEM) LL-37 concentration in patients with TB (13.94±5.13 ng/mL) was significantly higher than that in patients with Gram-positive bacteria-induced pneumonia (7.87±4.58 ng/mL, P=0.00077), in patients with Gram-negative bacteria-induced pneumonia (10.27±3.60 ng/mL, P=0.00730), and in control healthy subjects (1.75±0.71 ng/mL, P=0.00004).

Conclusion

Our data suggest that cathelicidin LL-37 is an important element of host defense in the course of bacterial diseases within the respiratory tract, particularly when the infection is caused by an intracellular pathogen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultAgedAntimicrobial Cationic PeptidesFemaleHumansMaleMiddle AgedPneumonia, BacterialTuberculosis, PulmonaryCathelicidins

Substanzen

Antimicrobial Cationic PeptidesCathelicidins

Autor:innen und Institutionen

  • Department of Experimental Immunology, Medical University of Lodz; Pulmonary Disease Hospital, Lodz . email@email.com.

Zitieren

APA

Majewski, K., Żelechowska, P., & Brzezińska-Błaszczyk, E. (2017). Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases. Clinical and Investigative Medicine, 40(1), E34-E39. https://doi.org/10.25011/cim.v40i1.28052

Vancouver

Majewski K, Żelechowska P, Brzezińska-Błaszczyk E. Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases. Clinical and Investigative Medicine. 2017;40(1):E34-E39. doi:10.25011/cim.v40i1.28052

BibTeX
@article{Majewski2017,
  author = {Majewski, Karol and Żelechowska, Paulina and Brzezińska-Błaszczyk, Ewa},
  title = {Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases},
  journal = {Clinical and Investigative Medicine},
  year = {2017},
  volume = {40},
  number = {1},
  pages = {E34--E39},
  doi = {10.25011/cim.v40i1.28052}
}
Kostenlos starten →